CeMines(TM) Creates 'BioSystems Division'
New operating unit, which will offer products and services to the research and drug discovery markets, continues CeMines' aggressive expansion
Evergreen. CeMines(TM) Inc., a privately held company founded in 2000 that employs genomics and proteomics information as building blocks for the development of early-stage diagnostics of diseases and therapeutics targeted for gene regulation, today announced that the company has created a new business unit: the CeMines BioSystems Division. Roger Attick, president & chief executive officer of CeMines, stated: "This newest business unit is a catalyst for bifurcated growth. We have created the infrastructure necessary to enable CeMines to immediately accelerate the growth of sales from our existing product line of Research Tools, including antibodies, cDNA and mRNA, and at the same time commence with our market introduction of a new family of products targeted at establishing CeMines as a premier brand in drug discovery and other markets."
Creation of the new BioSystems Division comes on the heels of an announcement in June that CeMines has expanded its Diagnostics & Therapeutics Research Division and relocated it from Los Angeles to La Jolla, Calif. The new 9,000-square-foot, state-of-the-art facility in La Jolla is a substantial increase in R&D space-expansion made necessary by the Company's aggressive growth expectations to support preparation for clinical trials in the U.S. and Europe, and to introduce new products.
"Looking back," said Attick, "our Research Tools group enabled CeMines to develop critical revenue channels during the early stages of our R&D in molecular diagnostics and therapeutics. Simply stated, we seized these opportunities for revenues by selling Research Tools into the academia and research markets. The early revenues helped subsidize a good portion of operating expense during the critical stages of our development.
"Times are changing in Life Sciences. It is clear to us that it is now time for CeMines to become a more aggressive competitor. The BioSystems Division is developing product kits, integrated with applications, that will enable our customers-researchers and drug development companies-to advance the progress of their own product development and research," said Roger Attick, who also is acting general manager of the new division. "Recent R&D advances at CeMines can now be further leveraged, thereby enabling CeMines to begin a new phase of market growth. This is extremely important, especially considering that CeMines is preparing to usher-in our first diagnostic products for large-scale clinical trials here in the United States," stated Attick.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
